The antigenic relationships between Epstein-Barr (EB) virus and herpesvirus saimiri (HVS) have been investigated in comparative immunofluorescence, microimmunodiffusion and serum neutralization tests. No similarity was detected between the structural antigens of the two herpesviruses but the results of microimmunodiffusion tests showed that they shared a non-structural, virus-determined antigen. The implications of this finding are discussed in relation to the importance of HVS and its monkey lymphoma as a model system of herpesvirus oncogenesis.
INTRODUCTION
Epstein-Barr (EB) virus is closely associated with two human neoplastic diseases, namely African Burkitt's lymphoma and nasopharyngeal carcinoma (Epstein & Achong, 1973; Henle & Henle, 1973; Klein, 1973) but final proof of this agent's oncogenicity by experimental inoculation of the virus into human subjects is clearly unattainable. The isolation of herpesvirus saimiri (HVS; Mel6ndez et al. 1969a; Morgan et al. 1970 ) with its ability to produce a fatal lymphoma in subhuman primates (Mel6ndez et al. 1969 b; Hunt et al. 197o) was therefore of special significance, since this agent provides an animal model for the study of tumour induction by a herpesvirus in a species phylogenetically related to man. In this context, knowledge of the biological relatedness of HVS and EB virus was thought likely to be of interest, and the present paper reports the results of comparative immunofluorescence, microimmunodiffusion and serum neutralization tests undertaken to investigate antigenic relationships between these two herpes viruses.
METHODS
Cells and technique of culture. Owl monkey kidney (OMK) cells of the 21o line were grown and infected with HVS by methods described previously (Morgan, Achong & Epstein, 1973; Morgan & Epstein, I977) . Lymphoid cells of the P3HR-1 (Hinuma et al. I967a) and B95-8 (Miller et al. I97 z) lines used as a source of EB virus were cultured as described by Rickinson et al. (1974) .
Virus. Stock pools of infectious HVS were prepared and assayed as in earlier work (Morgan, Achong & Epstein, i976) ; stock pools of infectious EB virus were made from B95-8 cultures by passing the medium through a o.45/~m millipore filter. The EB virus stocks were stored at -7o°C and subsequently titrated in a transformation assay as described by Rickinson et al. (I974) .
Preparation of cell extracts.
Complete extracts of either HVS-infected OMK cells (HVS-OMK extract) or EB virus-carrying P3HR-I cells (EBV-LC extract) were used as antigens in microimmunodiffusion tests and for the inoculation of rabbits. The HVS-OMK extract was prepared from about IO ° OMK cells showing advanced c.p.e. 5 days after infection with o.I p.f.u./cell of HVS; the cells were washed, suspended in 60 ml of PBS, and then sonicated as in earlier work (Morgan et al. 1973) . Coarse debris was deposited by centrifugation at 700 g for I5 min, washed twice with PBS, and the resulting supernatants were pooled and centrifuged further at 7000 g, for 30 min. The final pellet of small membrane debris was discarded and the supernatant from this faster run was passed successively through millipore filters of pore size 1.2/zm and 0"45 #m. The filtrate was concentrated through a dialysis membrane in Aquacide I-A (Calbiochem Ltd, London), dialysed in PBS, divided into I ml lots and stored at -70 °C.
The EBV-LC extract was prepared from about 3 x IO 9 P3HR-I cells which had been fed 4 days previously. At this time, 25 ~ of the cells were found by electron microscopy to contain virus. The cells were washed and suspended in 6o ml of PBS, and the EBV-LC extract was prepared from them in the same way as described for the HVS-OMK extract.
Preparation ofantisera. Antisera to HVS-OMK or EBV-LC extracts were raised in young adult, Californian rabbits. Three rabbits were injected subcutaneously and intramuscularly nine times at weekly intervals with I ml of extract emulsified in I ml of Freund's complete adjuvant, and were bled I week after the last injection. Antiserum to HVS capsid antigens was produced according to methods described elsewhere (Morgan & Epstein, I977) ; serum from a normal donor positive at I/I28 for EB virus in the indirect immunofluorescence test (Henle & Henle, 1966) was used as EB virus capsid antiserum. HVS neutralizing antiserum was produced in adult goats injected with I ml of HVS-OMK extract emulsified in 2 ml of Freund's complete adjuvant at multiple subcutaneous and intramuscular sites five times at weekly intervals, and bled I week after the last injection. A standard plaque-reduction assay (Habel, I969) with HVS showed that the goat-HVS neutralizing antiserum abolished plaque formation when used neat, whilst a I[IO dilution produced a 90 ~ reduction.
Absorption of antisera. The absorption and authentication of HVS-capsid antiserum bare already been described (Morgan & Epstein, 1977 )-Antiserum to EBV-LC extract was absorbed by similar methods except that the following absorbing reagents were used: (1) I g of freeze-dried foetal spleen or liver powder, (2) o.2 ml of foetal calf serum (FCS), and (3) o.2 ml of EB virus-negative human globulin per I ml antiserum. Both the antiserum to HVS-OMK extract and the goat-HVS neutralizing antiserum were absorbed with OMK cells and FCS (Morgan & Epstein, I977) .
Immunofluorescence tests. For immunofluorescence, FITC conjugates were prepared essentially by the methods of Elson, Singh & Taylor (1973) , whereby rabbit or human lgG eluted from a DEAE-cellulose column was inoculated into a sheep. The sheep serum was passed through a Sepharose 2B-IgG column with the human or rabbit IgG bound to the Sepharose by the cyanogen bromide technique (Axen, Porath & Ernback, 1967) . Specific IgG antibody was finally eluted from the column with o.2 M-propionic acid, dialysed in PBS and conjugated with FITC at 4 °C for 24 h.
In the tests, coverslip cultures of OMK cells showing foci of c.p.e. 3 to 5 days after infection with I p.f.u./cell of HVS were fixed in acetone at -60 °C, exposed to EB virus capsid antiserum at I[lO for I h at room temperature followed by 12 h at 4 °C, washed in PBS, reacted with sheep anti-human IgG (S-HulgG) antibody-FITC conjugate, washed again, mounted in IO ~ PBS in glycerol, and examined in a Leitz Orthoplan fluorescence microscope. Control procedures were: (a) infected OMK cells treated with Eagle's minimal essential medium (MEM) and EB seronegative human serum followed by S-HulgG antibody-FITC conjugate; (b) infected OMK cells reacted with absorbed HVS capsid antiserum at I/8 or normal rabbit serum followed by sheep anti-rabbit IgG (S-RIgG) antibody-FITC conjugate.
Acetone-fixed smears of EB3 Burkitt lymphoblasts (Epstein, Barr & Achong, x965) were treated with absorbed HVS capsid antiserum at I[8 for I h at 37 °C, washed again, nlounted, and examined in the fluorescence microscope. Control procedures were: (a) EB3 lymphoblasts tested with MEM and normal rabbit serum followed by S-RIgG antibody-FITC conjugate; (b) EB3 lymphoblasts reacted with EB virus capsid antiserum at I/8 or EB seronegative human serum followed by S-HulgG antibody-FITC conjugate.
Gel diffusion tests. Microimmunodiffusion tests were carried out according to the method of Crowle (1958) using o.6 ~ agar in tris-HC1. Freeze-dried foetal spleen, foetal liver and OMK cells were each reconstituted in I ml of PBS before use whilst HVS-OMK and EBV-LC extracts were thawed from -7o °C and used directly. The reagents were allowed to react at 4 °C for 3 days in the gels, and precipitation lines were then sought with a dissecting microscope.
Serum neutralization tests. In neutralization tests, o.I ml of neat control or goat-HVS antiserum inactivated by heating at 56 °C for 3o min, was mixed for I h at 37 °C with o'9 ml of an EB virus preparation containing lO 4 median transforming doses/ml; the virus-serum mixtures, either neat or further diluted I/IO in culture medium, were then added to 2"5 × lO 6 cord blood leucocytes which were left suspended in the mixtures for I h at 37 °C. After this the cells were deposited by centrifugation, washed twice in MEM, resuspended in I-6 ml of fresh culture medium, and distributed in o.2 ml volumes in the wells of microtest plates; the cultures were observed twice weekly for up to 4 weeks on an inverted microscope. Human serum, either EB seronegative or with known EB virus neutralizing titres at l/ZO, or normal goat serum, were used as the controls in the virus-serum mixtures, and in addition normal goat serum or goat-HVS neutralizing antiserum were mixed only with culture medium and added to foetal leukocytes to test for toxicity.
RESULTS

Immunofluorescence tests
In reciprocal immunofluorescence tests to compare the capsid antigens of EB virus and HVS, fluorescence was not detected in HVS-infected OMK cells tested with EB virus capsid antiserum followed by S-HuIgG antibody-FITC conjugate or in EB 3 lymphoblasts exposed to absorbed HVS capsid antiserum followed by S-RIgG antibody, FITC conjugate. On the other hand, infected OMK cells showed a characteristic, intranuclear, inclusion body-like fluorescence when reacted with absorbed HVS capsid antiserum (Morgan & Epstein, 1977) whilst EB 3 lymphoblasts treated with EB virus capsid antiserum, contained about Io ~ of cells with a positive, bright green staining in both the nucleus and cytoplasm. EB3 lymphoblasts and infected OMK cells were negative for fluorescence when exposed either to MEM, EB virus seronegative human serum or normal rabbit serum, followed by the appropriate FITC-conjugated antibody.
Gel diffusion tests
The results of comparative microimmunodiffusion tests showed that, after complete absorption, antiserum obtained from one rabbit inoculated with EBV-LC extract gave 5 lines of precipitation (Fig. I a) (5), EB virusnegative human globulin (6) and foetal liver (7). The absorbed antiserum gave 5 lines of precipitation with EBV-LC extract. The strongest of these lines (arrow) showed the common identity of an antigen present in both EBV-LC extract and HVS-OMK extract. The specificity of the antiserum is shown by the absence of lines with any of the other reagents in the test. In (b), absorbed antiserum to HVS-OMK extract (I)was reacted with HVS-OMK extract (2), EBV-LC extract (3), FCS (4), O M K cells (5), PBS (6) and foetal liver (7). The absorbed antiserum gave 9 lines of precipitation with HVS-OMK extract, but no lines developed with the other reagents.
detected between the absorbed antiserum and either FCS, EB virus-negative human globulin, foetal liver, foetal spleen (not shown) or normal OMK cells (Fig. i a) . The strongest of the lines (Fig. x a, arrow) showed the common identity of an antigen present in both the EBV-LC and HVS-OMK extracts. Antiserum obtained from two rabbits inoculated with HVS-OMK extract gave 9 lines of precipitation when absorbed and subsequently tested against HVS-OMK extract (Fig. I b) whilst no lines developed with EBV-LC extract. The absorbed antiserum did not give precipitation lines with OMK cells, FCS, foetal liver or PBS (Fig. I b) .
Serum neutralization tests
In the neutralization experiments, goat-HVS neutralizing antiserum did not inhibit EB virus-induced transformation of foetal leukocytes. Transformation, indicated by the appearance of progressively growing clumps of cells, was observed in all foetal leukocyte cultures previously exposed to virus-serum mixtures containing either goat HVS-neutralizing antiserum, EB seronegative human serum or normal goat serum. Transformation failed to occur in foetal leukocyte cultures which had been exposed to the mixture of virus and EB neutralizing serum. MEM, normal goat serum, or goat-HVS neutralizing antiserum had no effects on the leukocyte cultures.
DISCUSSION
Several lines of evidence point to the fact that the indirect immunofluorescence test (Henle & Henle, 1966) detects EB virus capsid antigens in those lymphoblasts in cultures which are undergoing a productive cycle of infection with the virus (Hinuma et al. I967b; zur Hausen et al. 1967; Epstein & Achong, 1968; Henle & Henle, ~968) . The specificity of the HVS capsid antiserum used here has been established by the stringent absorption and authentication procedures developed in earlier work {Morgan & Epstein, 1977) . Furthermore, both the sensitivity and specificity of the immunofluorescence tests in general were confirmed by the results obtained with the positive and negative control reagents, and by the specificity of the FITC-conjugated antibody preparations used (Morgan & Epstein, 1977) . The finding that positive reactions occurred only when EB virus-containing lymphoblastoid cells or HVS-infected OMK cells were tested with the homologous antiserum to virus capsid antigen indicates that no similarities exist between the capsid antigens of the two viruses.
In considering the neutralization experiments it is important to note that EB virusneutralizing serum ti'om a case of acute infectious mononucleosis has already been shown not to neutralize the infectivity of HVS (Mel6ndez et al. I969a) which fits well with the results of the present work in which a potent HVS-neutralizing antiserum failed to inhibit EB virus-induced transformation of cultured cord blood leukocytes. Taken together, these findings strongly suggest that no similarity exists between a second group of structural antigens, namely the membrane antigens, which are presumably associated with infectivity in these two viruses.
Although the production of antisera to crude extracts of virus-infected cells invariably leads to the development of antibodies to both virus and non-virus antigens, the resulting antisera can be made specific for virus antigens by careful absorption with normal constituents of the cell culture in which the virus was grown. The absence of precipitation lines between absorbed antiserum to EBV-LC extract and foetal liver, foetal spleen, OMK cells, EB virus-negative human globulin, and FCS (Fig. I a) confirmed the specificity of the antiserum for EB virus antigens. Absorbed antiserum to HVS-OMK extract was likewise shown to be specific for HVS-associated antigens since no precipitation lines developed with OMK cells or FCS (Fig. I b) .
Thus, the positive finding reported here, namely a common antigen present in both HVS-OMK and EBV-LC extracts (Fig. I a) , appear authentic. Although the common identity of this shared antigen was readily demonstrable with antiserum to EBV-LC extract, the failure to observe such a reaction with antiserum to HVS-OMK extract may perhaps result from the well-known variation in immunological responsiveness of individual animals, particularly when exposed to preparations such as HVS-OMK extract which contain mulv tiple antigens each at differing concentrations from the other (Ivfinyi &Cern#, 1969) .
In considering the nature of this shared antigen, it is evident that the absence of cross reactivity between the structural antigens of HVS and EB virus points firmly to its identity as a non-structural, virus-determined antigen. However, in the wider context of a herpesvirus group-specific antigen it is difficult to equate the soluble, diffusable antigen demonstrated in the present work with the structural antigen, presumably a virus capsid component, apparently shared by EB virus and a number of other herpesviruses (Evans et al. I972; Kirkwood, Geering & Old, I972; Ross, Frazier & Biggs, 1972 ) irrespective of their association with malignant disease. Although wider comparisons are needed to see whether the present common antigen is unique for oncogenic herpesviruses, the finding that EB virus shares such an antigen with a herpesvirus which causes a fatal lymphoma in subhuman primates is of considerable significance, and reaffirms the importance of this model system as a tool with which to investigate further the complex biological relationships of EB virus and human malignant disease.
